Report of the Fifteenth International Symposium of the Foundation for Promotion of Cancer Research: New Horizons in the Diagnosis and Treatment of Hematological Malignancies Based on Molecular Genetic Features

Pratik S. Multani, Kensei Tobinai, Tadao Kakizoe, James Olen Armitage, Ryuzo Ohno, Takashi Sugimura

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

The Fifteenth International Symposium of the Foundation for Promotion of Cancer Research entitled 'New Horizons in the Diagnosis and Treatment of Hematological Malignancies Based on Molecular Genetic Features' was held in Tokyo on January 15-17, 2002. Twenty-nine invited speakers, including 12 from abroad and 17 from Japan, presented the updated results of their research. After an overview of the classification of hematological malignancies, new findings on some disease entities based on novel immunophenotypic and molecular genetic features were presented. The results of gene expression profiling and BCL6 and C-MYC gene rearrangement in diffuse large B-cell lymphoma were presented and oncogenic mechanism of acute myeloid leukemia was discussed. In the treatment of non-Hodgkin's lymphoma and acute leukemia, the present consensus and future directions were discussed based on the results of multicenter trials in the USA and Japan. As a molecular targeting therapy, the remarkable effect of a BCR-ABL tyrosine kinase inhibitor, STI571, in chronic myeloid leukemia and gastrointestinal stromal tumor was presented. Thereafter, promising results of active immunotherapy, chimeric anti-CD20 monoclonal antibody, anti-CD20 radioimmunoconjugate and anti-CD22 immunotoxin for B-cell lymphoma were presented. Finally, recent advances in allogeneic hematopoietic stem cell transplantation were discussed, focusing on reduced-intensity preparative regimens. The recent advances in basic and clinical research on hematological malignancies would lead to further improvement in the prognosis and quality of life of patients suffering from leukemia or lymphoma.

Original languageEnglish (US)
Pages (from-to)371-385
Number of pages15
JournalJapanese Journal of Clinical Oncology
Volume32
Issue number9
DOIs
StatePublished - Sep 1 2002

Fingerprint

Hematologic Neoplasms
Molecular Biology
Japan
Leukemia
Research
Immunoconjugates
Immunotoxins
Active Immunotherapy
Neoplasms
Gastrointestinal Stromal Tumors
Lymphoma, Large B-Cell, Diffuse
Tokyo
Gene Rearrangement
Hematopoietic Stem Cell Transplantation
Gene Expression Profiling
B-Cell Lymphoma
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Acute Myeloid Leukemia
Protein-Tyrosine Kinases
Non-Hodgkin's Lymphoma

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Cite this

Report of the Fifteenth International Symposium of the Foundation for Promotion of Cancer Research : New Horizons in the Diagnosis and Treatment of Hematological Malignancies Based on Molecular Genetic Features. / Multani, Pratik S.; Tobinai, Kensei; Kakizoe, Tadao; Armitage, James Olen; Ohno, Ryuzo; Sugimura, Takashi.

In: Japanese Journal of Clinical Oncology, Vol. 32, No. 9, 01.09.2002, p. 371-385.

Research output: Contribution to journalArticle

@article{8b6dcca5d1ac4489b66e0afc9be9a12a,
title = "Report of the Fifteenth International Symposium of the Foundation for Promotion of Cancer Research: New Horizons in the Diagnosis and Treatment of Hematological Malignancies Based on Molecular Genetic Features",
abstract = "The Fifteenth International Symposium of the Foundation for Promotion of Cancer Research entitled 'New Horizons in the Diagnosis and Treatment of Hematological Malignancies Based on Molecular Genetic Features' was held in Tokyo on January 15-17, 2002. Twenty-nine invited speakers, including 12 from abroad and 17 from Japan, presented the updated results of their research. After an overview of the classification of hematological malignancies, new findings on some disease entities based on novel immunophenotypic and molecular genetic features were presented. The results of gene expression profiling and BCL6 and C-MYC gene rearrangement in diffuse large B-cell lymphoma were presented and oncogenic mechanism of acute myeloid leukemia was discussed. In the treatment of non-Hodgkin's lymphoma and acute leukemia, the present consensus and future directions were discussed based on the results of multicenter trials in the USA and Japan. As a molecular targeting therapy, the remarkable effect of a BCR-ABL tyrosine kinase inhibitor, STI571, in chronic myeloid leukemia and gastrointestinal stromal tumor was presented. Thereafter, promising results of active immunotherapy, chimeric anti-CD20 monoclonal antibody, anti-CD20 radioimmunoconjugate and anti-CD22 immunotoxin for B-cell lymphoma were presented. Finally, recent advances in allogeneic hematopoietic stem cell transplantation were discussed, focusing on reduced-intensity preparative regimens. The recent advances in basic and clinical research on hematological malignancies would lead to further improvement in the prognosis and quality of life of patients suffering from leukemia or lymphoma.",
author = "Multani, {Pratik S.} and Kensei Tobinai and Tadao Kakizoe and Armitage, {James Olen} and Ryuzo Ohno and Takashi Sugimura",
year = "2002",
month = "9",
day = "1",
doi = "10.1093/jjco/hyf080",
language = "English (US)",
volume = "32",
pages = "371--385",
journal = "Japanese Journal of Clinical Oncology",
issn = "0368-2811",
publisher = "Oxford University Press",
number = "9",

}

TY - JOUR

T1 - Report of the Fifteenth International Symposium of the Foundation for Promotion of Cancer Research

T2 - New Horizons in the Diagnosis and Treatment of Hematological Malignancies Based on Molecular Genetic Features

AU - Multani, Pratik S.

AU - Tobinai, Kensei

AU - Kakizoe, Tadao

AU - Armitage, James Olen

AU - Ohno, Ryuzo

AU - Sugimura, Takashi

PY - 2002/9/1

Y1 - 2002/9/1

N2 - The Fifteenth International Symposium of the Foundation for Promotion of Cancer Research entitled 'New Horizons in the Diagnosis and Treatment of Hematological Malignancies Based on Molecular Genetic Features' was held in Tokyo on January 15-17, 2002. Twenty-nine invited speakers, including 12 from abroad and 17 from Japan, presented the updated results of their research. After an overview of the classification of hematological malignancies, new findings on some disease entities based on novel immunophenotypic and molecular genetic features were presented. The results of gene expression profiling and BCL6 and C-MYC gene rearrangement in diffuse large B-cell lymphoma were presented and oncogenic mechanism of acute myeloid leukemia was discussed. In the treatment of non-Hodgkin's lymphoma and acute leukemia, the present consensus and future directions were discussed based on the results of multicenter trials in the USA and Japan. As a molecular targeting therapy, the remarkable effect of a BCR-ABL tyrosine kinase inhibitor, STI571, in chronic myeloid leukemia and gastrointestinal stromal tumor was presented. Thereafter, promising results of active immunotherapy, chimeric anti-CD20 monoclonal antibody, anti-CD20 radioimmunoconjugate and anti-CD22 immunotoxin for B-cell lymphoma were presented. Finally, recent advances in allogeneic hematopoietic stem cell transplantation were discussed, focusing on reduced-intensity preparative regimens. The recent advances in basic and clinical research on hematological malignancies would lead to further improvement in the prognosis and quality of life of patients suffering from leukemia or lymphoma.

AB - The Fifteenth International Symposium of the Foundation for Promotion of Cancer Research entitled 'New Horizons in the Diagnosis and Treatment of Hematological Malignancies Based on Molecular Genetic Features' was held in Tokyo on January 15-17, 2002. Twenty-nine invited speakers, including 12 from abroad and 17 from Japan, presented the updated results of their research. After an overview of the classification of hematological malignancies, new findings on some disease entities based on novel immunophenotypic and molecular genetic features were presented. The results of gene expression profiling and BCL6 and C-MYC gene rearrangement in diffuse large B-cell lymphoma were presented and oncogenic mechanism of acute myeloid leukemia was discussed. In the treatment of non-Hodgkin's lymphoma and acute leukemia, the present consensus and future directions were discussed based on the results of multicenter trials in the USA and Japan. As a molecular targeting therapy, the remarkable effect of a BCR-ABL tyrosine kinase inhibitor, STI571, in chronic myeloid leukemia and gastrointestinal stromal tumor was presented. Thereafter, promising results of active immunotherapy, chimeric anti-CD20 monoclonal antibody, anti-CD20 radioimmunoconjugate and anti-CD22 immunotoxin for B-cell lymphoma were presented. Finally, recent advances in allogeneic hematopoietic stem cell transplantation were discussed, focusing on reduced-intensity preparative regimens. The recent advances in basic and clinical research on hematological malignancies would lead to further improvement in the prognosis and quality of life of patients suffering from leukemia or lymphoma.

UR - http://www.scopus.com/inward/record.url?scp=0036725811&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036725811&partnerID=8YFLogxK

U2 - 10.1093/jjco/hyf080

DO - 10.1093/jjco/hyf080

M3 - Article

C2 - 12417606

AN - SCOPUS:0036725811

VL - 32

SP - 371

EP - 385

JO - Japanese Journal of Clinical Oncology

JF - Japanese Journal of Clinical Oncology

SN - 0368-2811

IS - 9

ER -